Odem’s scope

Approximately 15% of all heart failure (HF) patients suffer from cardiac desynchrony, typically manifested by impaired activation and contraction of the left ventricle. This phenomenon deforms the normal cardiac contraction and results in impaired cardiac pumping. Patients with cardiac desynchrony suffer from progressive deterioration in their quality of life and increased mortality. 

 

The current treatment for cardiac desynchrony is based on cardiac pacing by a special pacemaker and leads setup that synchronize the contraction of the right and left ventricles. This treatment, termed ‘bi-ventricular pacing’ or ‘cardiac resynchronization therapy’ (CRT) was found to improve cardiac pumping. However, the current CRT approach suffers from limitations, and fails in about 40% of the patients.

 

Odem is developing an innovative line of new-designed minimally invasive tools for cardiac pericardial cavity access and treatments. The company focuses on developing tools to improve the currently full-of-drawbacks bi-ventricular pacing (CRT). In addition, the company’s line of tools opens the course for safe and easy minimally invasive access to various pericardial cavity manipulations, including drug delivery, epicardial ablation and pericardiocentesis.

 

A view from our window;

 the Jordan Valley and the Sea of Galilee

 

 

Founded in 2006, Odem is leaning on a combination of advanced engineering expertise and broad scientific collaboration to bring innovative thinking to the field of heart failure patient’s treatment.

The company operates at Meytag High Tech Venture Technological Incubator (www.meytag.co.il).